

Supplementary Table 1. Details of diagnoses and conditioning regimens in FQ and no-antibiotic prophylaxis cohorts

	FQ prophylaxis (n=43) N (%)	No-antibiotic prophylaxis (n=92) N (%)	p-value
Diagnoses			
Malignant	25 (58%)	74 (80%)	0.01
Acute Myeloid Leukemia/ myelodysplasia	16 (37%)	33 (36%)	
Acute lymphoblastic leukemia	6 (14%)	28 (30%)	
Myeloproliferative neoplasms	3 (7%)	10 (11%)	
Hodgkins Lymphoma	0	3 (3%)	
Non-malignant	18 (42%)	18 (20%)	
Aplastic anemia	16 (37%)	16 (17%)	
Inherited disorders	2 (5%)	2 (3%)	
Conditioning			
Myeloablative conditioning (MAC)	21 (49%)	54 (59%)	0.3
Busulfan/ Treosulfan	16 (37%)	23 (25%)	
Total Body Irradiation 12Gy	5 (12%)	31 (34%)	
Reduced-intensity conditioning (RIC)	5 (12%)	13 (14%)	
Fludarabine-Melphalan 140mg/m ²			
Non-myeloablative conditioning (NMA)	17 (39%)	25 (27%)	
Fludarabine-cyclophosphamide based			

Supplementary Table 2 : Subgroup analysis in haploidentical transplant cohort

	FQ prophylaxis (n=6) N (%) / median (IQR)	No Antibiotic prophylaxis (n=42) N (%) / median (IQR)	<i>p-value</i>
Neutrophil engraftment (days)	14 (11-18)	14 (11-33)	0.4
Incidence of gram-negative infection	1 (17%)	15 (36%)	0.6
Median Duration of IV Antibiotics (days)	12 (3-24)	14 (2- 41)	0.8
Median Days of hospitalization (days)	21.5 (17-32)	26 (14-54)	0.3
Incidence of acute GVHD (all grades)	5 (83%)	19 (45%)	0.2